Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

被引：0
|
作者：
Michael Pfeifer
Raymond R. Townsend
Michael J. Davies
Ujjwala Vijapurkar
Jimmy Ren
机构：
[1] Janssen Scientific Affairs,Perelman School of Medicine
[2] LLC,undefined
[3] University of Pennsylvania,undefined
[4] Janssen Research & Development,undefined
[5] LLC,undefined
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Canagliflozin; Sodium glucose co-transporter 2 (SGLT2) inhibitor; Type 2 diabetes; Blood pressure; Ambulatory blood pressure monitoring; Pulse pressure; Mean arterial pressure; Double product;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
    Boyle, Luke D.
    Wilding, John P. H.
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (03) : 375 - 391
  • [22] Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
    Baker, William L.
    Smyth, Lindsay R.
    Riche, Daniel M.
    Bourret, Emily M.
    Chamberlin, Kevin W.
    White, William B.
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (04) : 262 - 275
  • [23] Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
    Lamos, Elizabeth M.
    Younk, Lisa M.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (06) : 763 - 775
  • [24] Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice
    Aly M. Abdelrahman
    Yousuf Al Suleimani
    Asem Shalaby
    Mohammed Ashique
    Priyadarsini Manoj
    Abderrahim Nemmar
    Badreldin H. Ali
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392 : 45 - 53
  • [25] Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin
    Polidori, David
    Iijima, Hiroaki
    Goda, Maki
    Maruyama, Nobuko
    Inagaki, Nobuya
    Crawford, Peter A.
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1321 - 1326
  • [26] Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus
    Samukawa, Yoshishige
    Mutoh, Masaru
    Chen, Shi
    Mizui, Nobuo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 40 (08) : 1207 - 1218
  • [27] Effects of sodium glucose co-transporter 2 inhibitors on the kidney
    Rocha, Natalia de Albuquerque
    Neeland, Ian J.
    McCullough, Peter A.
    Toto, Robert D.
    McGuire, Darren K.
    DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (05): : 375 - 386
  • [28] Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
    Dandona, Paresh
    Chaudhuri, Ajay
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (05)
  • [29] Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
    Chilton, R.
    Tikkanen, I.
    Cannon, C. P.
    Crowe, S.
    Woerle, H. J.
    Broedl, U. C.
    Johansen, O. E.
    DIABETES OBESITY & METABOLISM, 2015, 17 (12): : 1180 - 1193
  • [30] Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
    Nicolle, Lindsay E.
    Capuano, George
    Fung, Albert
    Usiskin, Keith
    POSTGRADUATE MEDICINE, 2014, 126 (01) : 7 - 17
12345